Annick Moureau
Biographic Data
| ID | 7788417 |
|---|---|
| NAME | Annick Moureau |
| GIVEN NAMES | Annick |
| FAMILY NAME | Moureau |
| SIGNATURE | MOUREAU A |
| AFFILIATIONS | Sanofi (France) |
| ORCID | 0000-0002-5306-2833 |
| VERIFIED | Yes |
| TOTAL WORKS | 2 |
| TOTAL CITATIONS | 0 |
| WORKS AS AUTHOR | 2 |
| WORKS AS EDITOR | 0 |
| FIRST PUBLICATION YEAR | 2019 |
| LATEST PUBLICATION YEAR | 2021 |
| H-INDEX | 0 |
Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
No clinically significant changes in what is known or expected for IIV4 was reported for the 2019/20 season, which supports the overall safety profile
Meningococcal serogroups and surveillance
No prominent works on this page.
Meningococcal serogroups and surveillance
Enhanced passive safety surveillance of the quadrivalent inactivated split-virion influenza vaccine (IIV4) in Finland during the 2019/20 influenza season
No clinically significant changes in what is known or expected for IIV4 was reported for the 2019/20 season, which supports the overall safety profile
Adverse effect (1 work) · Antibody (1 work) · Biostatistics (1 work) · Drug-Induced Adverse Reactions (1 work) · Emergency Medicine (1 work) · Epidemiology (1 work) · Immunization (1 work) · Immunology (1 work) · Influenza vaccine (1 work) · Influenza Virus Research Studies (1 work)